ATOSSA THERAPEUTICS, INC. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a company at a critical inflection point, balancing high-potential clinical data against a fragile balance sheet. The transition to a multi-indication platform involving DMD and MAS is an ambitious move to diversify risk, but it simultaneously increases the capital requirements for a firm already struggling with a 'going concern' warning. The 2026 data calendar for the Karisma and EVANGELINE studies will be the ultimate arbiter of the company's value. Investors are essentially betting on a binary outcome: either the upcoming clinical readouts provide enough validation to secure a major partnership or a high-valuation capital raise, or the company will succumb to its burn rate and patent litigation. The successful execution of the reverse stock split to maintain Nasdaq compliance suggests a management team fighting for survival, but the fundamental risk remains the gap between current cash reserves and the cost of reaching an NDA filing.